{"gao_id": "GAO-17-564", "published": "2017-07-11T12:00:00Z", "released": "2017-07-11T08:00:00Z", "summary": "FDA's expanded access program allows patients with serious or life threatening illnesses access to certain drugs before it has approved them. FDA also requires that manufacturers submit data about adverse reactions to these drugs. While FDA has provided some guidance to manufacturers, FDA does not fully explain the few instances when it would use these data on adverse reactions. This may influence manufacturers' decisions to...", "title": "Investigational New Drugs: FDA Has Taken Steps to Improve the Expanded Access Program but Should Further Clarify How Adverse Events Data Are Used", "topics": ["Prescription drugs", "Physicians", "Medically necessary treatments", "Health Care", "Access to health care", "Patient care services", "Websites", "Diseases", "Food and drug legislation", "Drug approvals", "Drugs", "Substance abuse treatment", "Internal controls", "Clinical trials", "Adverse events"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-17-564", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-17-564-highlights.pdf"}, {"title": "Full Report (52 pages)", "url": "https://www.gao.gov/assets/gao-17-564.pdf"}, {"title": "Accessible PDF (66 pages)", "url": "https://www.gao.gov/assets/690/685961.pdf"}]}